“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine disease (MSUD) prevented newborn death, normalized growth, restored ...

Artificial intelligence is making waves across industries, but its impact is higher in some sectors than others. Medicine and other sciences stand to gain much from this technology, thanks to their ...

Recombinase efficiency increases allow Qi Biodesign to insert 20-30 kb (5 or 6 genes) at one time at one location across a variety of different crop genetics. In addition, a large team at Qi Biodesign ...

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis. Decades ago, adding ...

A recent study by the University of Cologne has illuminated a specific tau protein's role in the progression of Alzheimer's ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Columnist Jennifer Lynne assesses the effects of Pfizer's decision to halt production of its hemophilia B gene therapy, Beqvez.

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...